贝瑞基因
(000710)
| 流通市值：43.14亿 | | | 总市值：46.28亿 |
| 流通股本：3.30亿 | | | 总股本：3.54亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 685,656,794.86 | 447,434,341.07 | 217,759,068.08 | 1,078,165,273.94 |
| 营业收入 | 685,656,794.86 | 447,434,341.07 | 217,759,068.08 | 1,078,165,273.94 |
| 二、营业总成本 | 713,217,299.16 | 456,188,384.03 | 214,518,555.65 | 1,072,541,450.25 |
| 营业成本 | 358,237,030.94 | 225,830,709.82 | 110,008,040.12 | 572,909,344.39 |
| 税金及附加 | 3,560,164.11 | 2,366,866.24 | 414,696.25 | 11,236,018.57 |
| 销售费用 | 156,278,837.86 | 100,519,226.84 | 47,819,719.97 | 236,830,171.84 |
| 管理费用 | 111,508,352.12 | 71,666,893.4 | 33,141,322.58 | 148,723,794.38 |
| 研发费用 | 78,716,866.22 | 52,519,317.48 | 21,653,803.47 | 95,419,662.22 |
| 财务费用 | 4,916,047.91 | 3,285,370.25 | 1,480,973.26 | 7,422,458.85 |
| 其中:利息费用 | 8,055,393 | 5,513,610 | 2,209,183.91 | 9,831,402.96 |
| 其中:利息收入 | -3,648,364.94 | 2,557,480.82 | -900,869.89 | 3,522,477.58 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,203,689.24 | 2,203,689.24 | -2,276,101.9 | -132,165.22 |
| 加:投资收益 | 4,650,790.35 | 3,257,567.49 | 954,578.63 | -14,553,527.69 |
| 资产处置收益 | -569,132.28 | -11,541.91 | -14,866.73 | 1,739,687.32 |
| 资产减值损失(新) | - | - | - | -28,078,288.63 |
| 信用减值损失(新) | -21,703,535.22 | -15,756,033.26 | -5,459,820.52 | -132,930,004.56 |
| 其他收益 | 854,181.34 | 578,844.32 | 425,716.91 | 1,717,510.77 |
| 四、营业利润 | -42,124,510.87 | -18,481,517.08 | -3,129,981.18 | -166,612,964.32 |
| 加:营业外收入 | 177,133.48 | 6,439.78 | 2,922.26 | 258,807.15 |
| 减:营业外支出 | 1,338,475.25 | 1,200,420.21 | 618,144.78 | 4,403,254.13 |
| 五、利润总额 | -43,285,852.64 | -19,675,497.51 | -3,745,203.7 | -170,757,411.3 |
| 减:所得税费用 | 7,136,143.7 | 5,734,665.27 | 1,894,516.73 | 17,417,622.98 |
| 六、净利润 | -50,421,996.34 | -25,410,162.78 | -5,639,720.43 | -188,175,034.28 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -50,421,996.34 | -25,410,162.78 | -5,639,720.43 | -188,175,034.28 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -52,563,718.07 | -27,242,543.15 | -6,462,206.12 | -192,428,499.73 |
| 少数股东损益 | 2,141,721.73 | 1,832,380.37 | 822,485.69 | 4,253,465.45 |
| 扣除非经常损益后的净利润 | -53,791,445.01 | -28,589,541.41 | -3,682,733.93 | -192,191,901.79 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.15 | -0.08 | -0.02 | -0.54 |
| (二)稀释每股收益 | -0.15 | -0.08 | -0.02 | -0.54 |
| 八、其他综合收益 | -10,490,907.17 | -3,950,510.27 | -814,304.19 | 5,461,696.08 |
| 归属于母公司股东的其他综合收益 | -2,317,678.96 | -3,294,200.76 | -669,245.91 | 4,595,883.99 |
| 九、综合收益总额 | -60,912,903.51 | -29,360,673.05 | -6,454,024.62 | -182,713,338.2 |
| 归属于母公司股东的综合收益总额 | -54,881,397.03 | -30,536,743.91 | -7,131,452.03 | -187,832,615.74 |
| 归属于少数股东的综合收益总额 | -6,031,506.48 | 1,176,070.86 | 677,427.41 | 5,119,277.54 |
| 公告日期 | 2025-10-31 | 2025-08-30 | 2025-04-28 | 2025-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |